ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)

Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced Last Patient Last Vi

Related Keywords

United States ,Boston ,Massachusetts ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Madrid ,Serbia ,San Diego ,California ,Bulgaria ,Germany ,Ashleyr Robinson ,Patricia Cobo Daniel Foley ,Michael Ropacki ,Carlos Buesa ,Data Monitoring Committee ,Lifesci Advisors ,Last Patient Visit ,Borderline Personality Disorder ,Interim Analysis ,Chief Medical Officer ,Secondary Progressive ,Kabuki Syndrome ,Personality Disorder ,Spanish Comisi ,Nacional Del Mercado De Valores ,Sci Advisors ,Phase Iib ,Iopharmaceutical Company ,Clinical Stage ,